MORRIS PLAINS, N.J., May 11 /PRNewswire-FirstCall/ -- Immunomedics,
Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing
monoclonal antibodies, today announced that Gerard G. Gorman, Vice
President of Finance and Chief Financial Officer, will be presenting at the
Rodman & Renshaw 3rd Annual Global Healthcare Conference scheduled for May
15 - 16, 2006 in Monte Carlo, Monaco.
Mr. Gorman's presentation, scheduled for Monday, May 15, 2006 at 3:20
p.m. (9:20 a.m. Eastern Time), will provide a corporate overview, including
comments on the Company's product portfolio and the recent licensing
agreement for future development of epratuzumab. In addition, he will
provide a summary of the dock and lock method - a new platform technology
for protein engineering. The presentation can be downloaded simultaneously
at http://www.immunomedics.com/1aboutus/rodmanrenshawmonaco.pdf.
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company focused on
the development of monoclonal, antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases. We have
developed a number of advanced proprietary technologies that allow us to
create humanized antibodies that can be used either alone in unlabeled or
"naked" form, or conjugated with radioactive isotopes, chemotherapeutics or
toxins, in each case to create highly targeted agents. Using these
technologies, we have built a pipeline of therapeutic product candidates
that utilize several different mechanisms of action. Our lead product
candidate, epratuzumab, which development, manufacture and
commercialization rights we have licensed to UCB, S.A. for the treatment of
all autoimmune indications worldwide, is currently in two pivotal Phase III
trials for the treatment of patients with moderate and severe lupus
(ALLEVIATE A and B). At present, there is no cure for lupus and no new
lupus drug has been approved in the U.S. in the last 40 years. We believe
that our portfolio of intellectual property, which includes approximately
90 patents issued in the United States, and more than 250 other issued
patents worldwide, protects our product candidates and technologies. Visit
our web site at http://www.immunomedics.com. We also have a majority
ownership in IBC Pharmaceuticals, Inc., which is developing a novel dock
and lock platform technology, and a new method of delivering imaging and
therapeutic agents selectively to disease, especially different solid
cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based,
pretargeting methods.
This release, in addition to historical information, may contain
forward- looking statements made pursuant to the Private Securities
Litigation Reform Act of 1995. Such statements, including statements
regarding clinical trials, out-licensing arrangements (including the timing
and amount of contingent payments), and capital raising activities, involve
significant risks and uncertainties and actual results could differ
materially from those expressed or implied herein. Factors that could cause
such differences include, but are not limited to, risks associated with new
product development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and
availability of required financing and other sources of funds on acceptable
terms, if at all, as well as the risks discussed in the Company's filings
with the Securities and Exchange Commission. The Company is not under any
obligation, and the Company expressly disclaims any obligation, to update
or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.
For More Information:
Dr. Chau Cheng
Associate Director, Investor Relations & Business Analysis
(973) 605-8200, extension 123
ccheng@immunomedics.com
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.Immunomedics.com
http://www.prnewswire.com/comp/113121.html /
CONTACT:
Dr. Chau Cheng, Associate Director, Investor
Relations & Business Analysis, +1-973-605-8200, ext. 123,
ccheng@immunomedics.com
|
